Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China National Accord MedicinesSZSE:000028 -1.00%57 Pretax Margin % is 2.44% as of Jun. 2026, which is 28% below its 10-year median of 3.40. GuruFocus rates SZSE:000028 with a GF Score™ of 57/100. The stock has 6 warning signs investors should review. Among 123 Medical Distribution companies, China National Accord Medicines ranks worse than 56.1% on this metric.
The historical rank and industry rank for China National Accord Medicines's Pretax Margin % or its related term are showing as below:
SZSE:000028'
s Pretax Margin % Range Over the Past 10 Years
Min: 0.77 Med: 3.4 Max: 3.89
Current: 1.95
SZSE:000028's Pretax Margin % is ranked worse than 56.1% of 123
companies
in the Medical Distribution industry
Industry Median: 2.25
vs SZSE:000028: 1.95
China National Accord Medicines (SZSE:000028) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
China National Accord Medicines Pretax Margin % Related Terms
China National Accord Medicines Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China National Accord Medicines Pretax Margin % Chart
SZSE:000028 vs MCK, COR, CAH: Pretax Margin % Comparison
For the Medical Distribution subindustry, China National Accord Medicines's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China National Accord Medicines Pretax Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China National Accord Medicines's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where China National Accord Medicines's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China National Accord Medicines (SZSE:000028) has a Pretax Margin % of 2.44% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on China National Accord Medicines and its competitors. This is 28% below median its historical median of 3.40. Over the past decade, China National Accord Medicines' Pretax Margin % has ranged from 0.77 to 3.89. According to the industry distribution chart, China National Accord Medicines ranks #69 out of 123 companies in the Medical Distribution industry, placing it in the top 56.1%.
Is China National Accord Medicines' Pretax Margin % too high?
China National Accord Medicines' current Pretax Margin % of 2.44% is 28% below median its 10-year median of 3.40. Over the past 10 years, this metric has ranged from a low of 0.77 to a high of 3.89. The Medical Distribution industry median Pretax Margin % is 2.25. China National Accord Medicines' value of 2.44% is 8.4% above this industry median. Based on the distribution chart, China National Accord Medicines ranks #69 out of 123 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, China National Accord Medicines has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does China National Accord Medicines' Pretax Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, China National Accord Medicines ranks #69 out of 123 companies for Pretax Margin %. This places China National Accord Medicines in the lower half of its industry. The industry median Pretax Margin % is 2.25. China National Accord Medicines' value of 2.44% is 8.4% above this benchmark. Historically, China National Accord Medicines' own Pretax Margin % has ranged from 0.77 to 3.89 over the past decade. While the company's 10-year median is 3.40 vs. the industry median of 2.25, China National Accord Medicines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Distribution company?
The median Pretax Margin % among Medical Distribution companies is 2.25, based on 123 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China National Accord Medicines's current Pretax Margin % of 2.44% is 8.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on China National Accord Medicines and its competitors. For the Medical Distribution industry, the median Pretax Margin % is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China National Accord Medicines's current Pretax Margin % is 2.44%, which is 28% below median its own 10-year median of 3.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Accord Medicines stock overvalued right now?
China National Accord Medicines (SZSE:000028) has a current Pretax Margin % of 2.44%. The current Pretax Margin % is 2.44%, which is 28% below median its 10-year median of 3.40 and 8.4% above the Medical Distribution industry median of 2.25. China National Accord Medicines' overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For China National Accord Medicines (SZSE:000028), the current Pretax Margin % is 2.44% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.
57GF Score
Get the complete analysis for SZSE:000028
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:000028 has been successfully added to your 
